Ryman Healthcare (NZSE:RYM) is back in focus after director James Miller signalled his intention to step down to prioritise his new role as Chair of the Financial Markets Authority.
See our latest analysis for Ryman Healthcare.
The recent reshuffle on Ryman Healthcare’s board comes at a time when the share price is around NZ$2.10, with short term share price returns mixed and longer term total shareholder returns still showing a pronounced decline over three and five years. This pattern suggests that, despite brief periods of positive momentum, investors remain cautious and are still reassessing risk around the company’s outlook.
If this governance change has you thinking more broadly about opportunities in related areas, it could be a good moment to scan the market using our healthcare focused screener for 131 healthcare AI stocks.
Given Ryman Healthcare’s share price slide over recent years and the fresh board reshuffle, the real issue now is whether the current valuation still compensates you for the risk you are taking on.
Most Popular Narrative: 30.1% Undervalued
Against the last close at NZ$2.10, the most followed narrative for Ryman Healthcare points to a higher fair value near NZ$3.01, built on a detailed turnaround story.
The company has embarked on a significant business reorganization to reduce costs and improve operational efficiency, including a focus on centralizing overheads and systems. This effort, resulting in $18 million in annualized savings, is expected to improve net margins over time.
Want to see what sits behind that margin reset and uplift in earnings power? The narrative leans on changing profit margins, revenue growth assumptions and a future earnings multiple that is very different from where Ryman Healthcare trades today.
Result: Fair Value of NZ$3.01 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Ryman Healthcare’s heavy debt load and recent losses, together with any renewed concerns about governance or financial reporting, could quickly challenge this positive turnaround narrative.
Find out about the key risks to this Ryman Healthcare narrative.
Another View On Ryman Healthcare’s Valuation
While the most followed narrative points to Ryman Healthcare being around 30.1% undervalued at a fair value of NZ$3.01, the current P/S ratio of 2.5x tells a tougher story. It is higher than both the Oceanic healthcare industry at 1.1x and the peer average at 2.3x, and it also sits above a fair ratio of 1.2x that the market could move towards over time. That gap implies investors are already paying a premium for future recovery, so the key question is whether you are comfortable underwriting that level of valuation risk.
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
If this mix of caution and potential around Ryman Healthcare leaves you undecided, move quickly. Review the full rewards breakdown and weigh things up for yourself with 2 key rewards
Looking for more investment ideas beyond Ryman Healthcare?
Do not stop with just one opportunity. Give yourself options by scanning broader ideas that could better match your return goals and comfort with risk.
- Target potential mispricing by checking companies on our 261 high quality undervalued stocks before other investors start paying closer attention.
- Strengthen your income potential and assess reliable cash payouts using the 435 dividend fortresses while yields are still compelling.
- Prioritise financial resilience and sleep easier at night by reviewing companies in the 288 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com